ANGELA BIEMAN: Open Payments
NPI 1386294635 · SUMMIT, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$306 in 19 payments from 6 companies in 2025. Trend: 2023 $180 · 2024 $416 · 2025 $306
Food & beverage: $306
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 6 | $102 |
| ABBVIE INC. | 5 | $82 |
| Madrigal Pharmaceuticals | 4 | $58 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $29 |
| Blueprint Medicines Corporation | 1 | $18 |
| ViiV Healthcare Company | 1 | $17 |
Products named: TRELEGY ELLIPTA, RINVOQ, REZDIFFRA, XIFAXAN, SKYRIZI, AYVAKIT, APRETUDE, NUCALA.
Industry payments across NJ — which companies pay providers there.
